The litigation centers on allegations that Capricor misled shareholders regarding its lead cell therapy, Deramiocel. According to the complaint, the company modified its statistical analysis plan for clinical data without prior FDA agreement before resubmitting its Biologics License Application. These undisclosed changes reportedly created significant regulatory risks, casting doubt on the therapy's path toward approval for Duchenne muscular dystrophy.

Investors who acquired stock during the specified class period may seek compensation through a contingency fee arrangement. While a lawsuit has been filed, no class has been certified, meaning shareholders are not currently represented by counsel unless they choose to retain their own. Those interested in participating or serving as a representative may contact Phillip Kim at the Rosen Law Firm for further legal guidance.